NOW Diagnostics Acquires CELLMIC Reader Technology

Strengthens Rapid Diagnostics and Point-Of-Care Testing Capabilities

SPRINGDALE, Ark.–(BUSINESS WIRE)–#ADEXUSDxNOW
Diagnostics Inc.
announced today that it has acquired the rapid
assay reader product lines and related assets of mobile diagnostics
company CELLMIC
LLC
.

NOW Diagnostics Inc., based in Springdale, Arkansas, is a leader in
innovative diagnostics testing. Its ADEXUSDx® product line
features a “lab at your fingertip” concept, using a single drop of blood
to test for a variety of common conditions, illnesses and diseases, with
results in a matter of minutes.

Founded in 2011 as Holomic LLC – a spinoff of Prof. Aydogan Ozcan’s
research lab at the UCLA Henry Samueli School of Engineering and Applied
Science – CELLMIC, LLC based in Inglewood, California, has developed a
series of smartphone-based, rapid assay readers with applications in
medical, veterinary, food safety, biodefense and drugs-of-abuse testing.
CELLMIC’s products carry the European Union CE Mark and are in use
around the world.

“This strategic acquisition strengthens our presence in the rapid
diagnostics and mobile health space,” said NOW Diagnostics’ CEO, Kevin
Clark. “This acquisition will allow us to integrate CELLMIC’s advanced
reader technology with our ADEXUSDx® testing platform, which
we expect will result in even more accurate results and provide
convenience, simplicity and cost benefits to U.S. and international
point-of-care testing and consumer healthcare markets. Our ADEXUSDx®
product line is built on the ‘lab at your fingertip’ concept as an
alternative to laboratory-based testing, and the addition of this new
reader technology from CELLMIC is expected to put digital analysis ‘in
the palm of your hand.’”

“NOW Diagnostics has been a valued partner of CELLMIC for over two
years,” noted CELLMIC’s CEO Neven Karlovac. “We believe that this
transaction will enable this superior reader technology to reach its
full commercial potential, both in combination with NOW Diagnostics’
rapid tests as well as through continued OEM partnerships. CELLMIC will
continue to develop and commercialize a strong IP portfolio supporting
additional biophotonics and mobile technologies, including lens-free
microscopes and ELISA microplate readers.”

NOW Diagnostics’ FDA-cleared and CE-Marked ADEXUSDx®
hCG
pregnancy test was the first registered product of the ADEXUSDx®
family.* The lateral-flow test enables a one-step, 10-minute process
using as little as a single drop of blood with no laboratory or
additional equipment required. Branded and marketed in Europe under the FIRST
TO KNOW®
trademark, it is the first over-the-counter
(OTC), blood-based pregnancy test for sale anywhere in the European
Union and is available at pharmacies in Italy through an exclusive
distribution agreement with Welcome
Pharma
.**

*The ADEXUSDx® test platform has undergone a rigorous
regulatory process in the U.S., receiving 510(k) clearance, CLIA
registration, and classification by the U.S. FDA.

**The FIRST TO KNOW® pregnancy test is not FDA-cleared for
OTC sale or for home use in the U.S.

About NOW Diagnostics, Inc.

NOW Diagnostics, Inc., based in Springdale, Arkansas, is a leader in
innovative diagnostics testing. Its ADEXUSDx
®
product line features a lab at your fingertip, using a single drop of
blood to test for a variety of common conditions, illnesses and
diseases, with results in a matter of minutes. By eliminating the need
to send tests to off-site laboratories, NOW Diagnostics products have
the potential to decrease the waiting period to determine test results
by days. For more information about NOW Diagnostics, visit
www.nowdx.com.
For more information about the ADEXUSDx
® hCG
pregnancy test, including its intended use, features, benefits and
limitations, and directions for use, visit
www.nowdx.com/products/hcg.
For more information on the FIRST TO KNOW
®
pregnancy test, including its intended use, features, benefits and
limitations, and directions for use, visit
www.firsttoknow.eu.

About Cellmic, LLC

Cellmic, LLC is a technology company dedicated to improving patient
healthcare with the use of smartphones and biophotonics. We are a
licensee of UCLA and collaborate closely with Professor Aydogan Ozcan
and his research group at the university. Our first commercialization
success was a product line of readers for lateral flow immunoassays that
is now part of NOW Diagnostics, Inc. Cellmic continues with
the commercialization of other technologies in our portfolio, including
microplate readers, lens-free holographic microscopes, and handheld
analyzers for blood count, allergens, and mercury contamination. The
company earned the Technology Pioneer 2015 award by the World Economic
Forum in Davos; was a finalist for the Katerva, Nokia Sensing
X-Challenge, and SPIE PRISM awards; and has won numerous government and
corporate contracts. For more information see 
www.cellmic.com.

Contacts

NOW Diagnostics Company Contact
Jeff
Ellis, VP Sales & Marketing
Phone: 479-966-4540
Email: jeff.ellis@nowdx.com
or
NOW
Diagnostics Media Contact

Armada Medical Marketing
Dan
Snyders
Phone: 720-231-9990
Email: dan@armadamedical.com
or
Cellmic,
LLC Contact

Neven Karlovac, CEO
Phone: 310-897-2096
Email:
nkarlovac@cellmic.com